TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ovid Therapeutics ( (OVID) ) has shared an update.
On September 11, 2025, Ovid Therapeutics Inc. announced that it has regained compliance with Nasdaq’s listing requirements, specifically maintaining a minimum bid price of at least $1.00 per share. This development closes the matter with Nasdaq, potentially stabilizing the company’s market position and reassuring stakeholders regarding its stock market standing.
The most recent analyst rating on (OVID) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.
Spark’s Take on OVID Stock
According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.
Ovid Therapeutics’ stock score is primarily influenced by its financial performance challenges, including revenue volatility and ongoing losses. The technical analysis indicates strong upward momentum, but the high beta suggests volatility. Valuation remains a concern with a negative P/E ratio and no dividend yield. Positive corporate events, such as the Nasdaq transfer and financial agreements, provide some stability and potential for future growth.
To see Spark’s full report on OVID stock, click here.
More about Ovid Therapeutics
Ovid Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing therapies for rare neurological disorders.
Average Trading Volume: 1,982,570
Technical Sentiment Signal: Hold
Current Market Cap: $91.02M
For a thorough assessment of OVID stock, go to TipRanks’ Stock Analysis page.